Natera NTRA recently announced the submission of a premarket approval (PMA) application to the FDA for its Signatera CDx test ...

February is National Cancer Prevention Month and to help people keep life flowing smoothly, the Urology Care Foundation (UCF), the official foundation of the American Urological Association (AUA), is ...

Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the activation of the NRG Oncology trial, ARCHER (NRG-GU015), a ...

Although bladder cancer ranks as the sixth most common cancer in the United States, with approximately 85,000 new cases diagnosed each year, it continues to receive limited awareness, advocacy, and ...

Out of sight, out of mind. A new study suggests a common eye condition could be quietly masking one of the only early warning ...

By Dr. Sanchari Sinha Dutta, Ph.D. A large electronic health record study suggests that difficulty recognizing painless blood ...

The earliest symptoms of bladder cancer may go unnoticed by patients with colorblindness or similar color vision deficiencies ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Recognizing the sight of blood in urine, the most common first sign of bladder cancer, is often the impetus that leads people ...

Inlexzo is a new treatment for a type of bladder cancer in adults that hasn’t spread to the muscles and doesn’t respond to Bacillus Calmette-Guérin (BCG) therapy. It’s approved for treating non-muscle ...

Colorblind people might have a unique disadvantage in noticing an early warning sign of certain cancers, a new study suggests.